Liminatus Pharma, Inc.
LIMNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Liminatus Pharma, Inc. (LIMN) is listed under Biotechnology. With a market capitalization of $3.9M, it sits in micro-cap territory. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Market Cap
$3.9M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-22.22
EPS (Fwd)
—
ROE
—
ROA
-95.7%
Cash
$3.0M
Total Debt
$1.4M
Free CF
-$10.0M
52W Change
-95.3%
Annual Financials
Cash vs Debt
Where LIMN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LIMN finished 53.99% below its 150-day moving average ($6.76) and 75.42% below its 200-day moving average ($12.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LIMN overbought or oversold?
At the October 20, 2026 close, LIMN's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Liminatus Pharma, Inc. holds $3.0M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$10.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
With cash comfortably exceeding debt, LIMN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Liminatus Pharma, Inc.'s trajectory.